Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders
Editor in chief: Jun WANG
Chinese Journal of Alzheimer's Disease and Related Disorders >
Clinical observation of galantamine hydrobromide combined with mannitol sodium in the treatment of cognitive impairment after stroke
Received date: 2024-01-30
Revised date: 2024-03-08
Online published: 2024-04-26
Objective: To investigate the clinical efficacy of galantamine hydrobromide combined with manamide sodium in the treatment of cognitive impairment after stroke. Methods: 130 stroke patients admitted to our hospital from June 2022 to December 2023, all with cognitive dysfunction, were divided into the combined group and the galantamine group according to envelope method; patients in the galantamine hydrobromide group were treated with galantamine hydrobromide; patients in the combined group were treated with manamide sodium combined treatment. The clinical efficacy of the two groups was compared. Neurological and cognitive function scores, serum HCY and NSE levels were compared between the two groups before and after treatment to observe the occurrence of adverse reactions. Results: Compared with galantamine hydrobromide group, the combined group had lower CSS score and higher MMSE score after treatment (P<0.05). Compared with galantamine hydrobromide group (86.15%), the therapeutic effect of combined group (95.38%) was significantly higher (χ2=10.883, P=0.004). After treatment, the levels of HCY and NSE in combination group were significantly lower than those in galantamine hydrobromide group (P<0.05). The incidence of adverse reactions in combination group (4.17%) was significantly lower than that in galantamine group (16.92%) (χ2=5.123, P=0.024). Conclusion: Galantamine hydrobromide combined with manamide sodium has significant clinical efficacy in the treatment of cognitive impairment after stroke, which can significantly improve the neurological function and cognitive function of patients, improve serological indexes, and alleviate adverse reactions, and is worthy of further clinical promotion.
Pida HAO , Yang WANG , Ran SU , Xiaojuan ZHAO , Kuanfei TANG , Yingke LIU , Yuling SHANG . Clinical observation of galantamine hydrobromide combined with mannitol sodium in the treatment of cognitive impairment after stroke[J]. Chinese Journal of Alzheimer's Disease and Related Disorders, 2024 , 7(2) : 110 -113 . DOI: 10.3969/j.issn.2096-5516.2024.02.005
表1 联合组和氢溴酸加兰他敏组患者临床疗效比较[例(%)]Tab 1 Comparison of clinical efficacy between combination group and galantamine hydrobromide group [n(%)] |
组别 | 例数 | 显效 | 有效 | 无效 | 总有效率 |
---|---|---|---|---|---|
联合组 | 65 | 39(60.00) | 23(35.38) | 3(4.62) | 62(95.38) |
加兰他敏组 | 65 | 21(32.31) | 35(53.85) | 9(13.84) | 56(86.15) |
χ2值 | 10.883 | ||||
P值 | 0.004 |
表2 联合组和氢溴酸加兰他敏组患者治疗前后CSS评分和MMSE评分比较($\bar{x}\pm s$,分)Tab 2 Comparison of CSS scores and MMSE scores before and after treatment between combination group and galantamine hydrobromide group ($\bar{x}\pm s$, score) |
组别 | CSS评分 | MMSE评分 | |||
---|---|---|---|---|---|
治疗前 | 治疗后 | 治疗前 | 治疗后 | ||
联合组(n=65) | 32.89±2.11 | 21.03±1.27* | 28.25±1.59 | 36.75±2.21* | |
加兰他敏组(n=65) | 32.56±2.04 | 25.29±1.61* | 27.95±1.54 | 33.38±2.05* | |
t值 | 0.907 | 11.749 | 1.093 | 9.013 | |
P值 | 0.366 | 0.000 | 0.276 | 0.000 |
注:与治疗前比较,*P<0.05 | |
Note: Compared with before treatment, *P<0.05 |
表3 联合组和氢溴酸加兰他敏组患者治疗前后血清HCY和NSE水平比较($\bar{x}\pm s$)Tab 3 Comparison of serum HCY and NSE levels in combination group and galantamine hydrobromide group before and after treatment ($\bar{x}\pm s$) |
组别 | HCY(μmol/L) | NSE(μg/L) | |||
---|---|---|---|---|---|
治疗前 | 治疗后 | 治疗前 | 治疗后 | ||
联合组(n=65) | 26.25±1.82 | 10.03±0.86* | 21.76±2.21 | 13.44±1.47* | |
加兰他敏组(n=65) | 26.71±1.85 | 17.77±1.29* | 21.95±2.24 | 17.64±1.96* | |
t值 | 1.429 | 29.849 | 0.487 | 13.821 | |
P值 | 0.155 | 0.000 | 0.627 | 0.000 |
注:与治疗前比较,*P<0.05 | |
Note: Compared with before treatment, *P<0.05 |
表4 联合组和加兰他敏组患者不良反应发生情况比较[例,(%)]Tab 4 Comparison of adverse reactions between combination group and galantamine group [n(%)] |
组别 | 例数 | 头晕 | 失眠 | 口干 | 头痛 | 总发生率 |
---|---|---|---|---|---|---|
联合组 | 65 | 1(1.54) | 1(1.54) | 0(0.00) | 1(1.54) | 3(4.62) |
加兰他敏组 | 65 | 2(3.08) | 3(4.62) | 3(4.62) | 3(4.62) | 11(16.92) |
χ2值 | 5.123 | |||||
P值 | 0.024 |
[1] |
|
[2] |
许济, 李花, 田苗, 等. 脑卒中后认知功能障碍发生率及其危险因素分析[J]. 安徽医药, 2021, 25(2):321-325.
|
[3] |
汪凯, 董强, 郁金泰, 等. 卒中后认知障碍管理专家共识2021[J]. 中国卒中杂志, 2021, 16(4):376-389.
|
[4] |
|
[5] |
吴孟娇, 王景信, 邵芃, 等. 甘露特钠胶囊治疗卒中后认知障碍的临床疗效分析[J]. 航空航天医学杂志, 2023.
|
[6] |
金庆文, 王颖. 氢溴酸加兰他敏胶囊改善老年及老年前期者记忆障碍的临床观察[J]. 脑与神经疾病杂志, 2024, 1(3):165-167.
|
[7] |
|
[8] |
|
[9] |
金庆文, 王颖. 氢溴酸加兰他敏胶囊改善老年及老年前期者记忆障碍的临床观察[J]. 脑与神经疾病杂志, 2024, 1997(3):165-167.
|
[10] |
尤丰玲, 夏高富, 蔡静, 等. 甘露特钠治疗阿尔茨海默病源性轻度认知障碍合并甲状腺功能减退症-桥本氏甲状腺炎1例[J]. 国际老年医学杂志, 2023, 44(1):125-128.
|
[11] |
|
[12] |
汪峰, 杨楠, 彭慧渊, 等. 脑小血管病认知障碍特点及与影像学总负荷评分的关系[J]. 中国实用神经疾病杂志, 2021, 24(1):7-12.
|
[13] |
李冬梅. 经颅磁刺激联合药物治疗阿尔茨海默病改善患者认知功能、精神行为症状及神经递质的效果[J]. 中国临床医生杂志, 2023, 51(10):1183-1185.
|
[14] |
王特, 赵伟, 刘艳, 等. 阿尔茨海默病采用甘露特钠配合多奈派齐治疗的效果[J]. 慢性病学杂志, 2023, 24(9):1425-1427.
|
[15] |
宋冬晶, 刘斌, 钟莺, 等. 甘露特钠胶囊联合盐酸多奈哌齐片治疗痴呆患者的临床疗效及安全性[J]. 阿尔茨海默病及相关病, 2022, 5(4):295-299.
|
[16] |
|
[17] |
杨乐, 刘婷婷, 刘丹, 等. 多种血清标志物预测老年急性缺血性脑卒中患者卒中后认知障碍的研究[J]. 神经疾病与精神卫生, 2024, 24(2):83-88.
|
[18] |
吴孟娇, 王景信, 邵芃, 等. 甘露特钠胶囊治疗卒中后认知障碍的临床疗效分析[J]. 航空航天医学杂志, 2023, 34(6):654-657.
|
/
〈 |
|
〉 |